140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)Adil Daud, A. Ribas, Jedd D. Wolchok et al.|European Journal of Cancer|2014Cited by 6
Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanomaRichard Kefford, Adil Daud, Omid Hamid et al.|Unknown|2014Cited by 0